Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs
TipRanks (Mon, 5-Jan 8:19 AM ET)
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
Business Wire (Mon, 5-Jan 7:30 AM ET)
Cybin Launches $100 Million At-The-Market Equity Program to Fuel Mental Health Drug Innovation
Market Chameleon (Wed, 31-Dec 3:41 AM ET)
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
Business Wire (Tue, 30-Dec 3:33 PM ET)
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Business Wire (Thu, 18-Dec 7:30 AM ET)
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
Business Wire (Thu, 13-Nov 7:21 AM ET)
Cybin Showcases Late-Stage Mental Health Innovations at Jefferies Global Healthcare Conference
Market Chameleon (Wed, 12-Nov 4:42 AM ET)
Cybin to Participate in the Jefferies Global Healthcare Conference in London
Business Wire (Wed, 12-Nov 7:30 AM ET)
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
Business Wire (Thu, 6-Nov 7:30 AM ET)
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Business Wire (Wed, 5-Nov 7:30 AM ET)
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Cybin Common Shares trades on the AMEX stock market under the symbol CYBN.
As of January 7, 2026, CYBN stock price was flat at $8.28 with million shares trading.
CYBN has a beta of 1.36, meaning it tends to be more sensitive to market movements. CYBN has a correlation of 0.15 to the broad based SPY ETF.
CYBN has a market cap of $413.20 million. This is considered a Small Cap stock.
In the last 3 years, CYBN traded as high as $13.88 and as low as $.17.
CYBN has underperformed the market in the last year with a return of -17.4%, while SPY returned +18.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CYBN shares. However, CYBN has outperformed the market in the last 3 month and 2 week periods, returning +36.4% and +1.5%, while SPY returned +3.4% and -0.1%, respectively. This indicates CYBN has been having a stronger performance recently.
CYBN support price is $7.89 and resistance is $8.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYBN shares will trade within this expected range on the day.
